AuthorCitation

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

Mellors, Patrick , Binder, Moritz , Buadi, Francis K. , Lacy, Martha Q. , Gertz, Morie A. , Hayman, Suzanne R. , Kapoor, Prashant , Gonsalves, Wilson I. , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Kourelis, Taxiarchis , Warsame, Rahma , Zeldenrust, Steven R., Lust, John A., Kyle, Robert A. , Kumar, Shaji , Mellors, Patrick W , Dispenzieri, Angela , Gonsalves, Wilson , Hwa, Yi L , Kourelis, Taxiarchis , Warsame, Rahma , Leung, Nelson , Go, Ronald S , Kyle, Robert A , Rajkumar, S Vincent , Kumar, Shaji K , Gertz, Morie A , Binder, Moritz , Buadi, Francis K , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Leukemia & Lymphoma | May 17, 2019 | Volume: 60 | Issue: 12 | Pages: 2960-2967

10.1080/10428194.2019.1613536 | PMID 31096812

Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment.

Kourelis, Taxiarchis , Kyle, Robert A. , Kumar, Shaji , Lacy, Martha Q. , Kapoor, Prashant , Lust, John A., Hayman, Suzanne R. , Zeldenrust, Steven R., Gertz, Morie A. , Buadi, Francis K. , Go, Ronald S. , Rajkumar, S. Vincent , Dingli, David , Lin, Yi , Leung, Nelson , Dispenzieri, Angela

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8594-8594

10.1200/jco.2015.33.15_suppl.8594

Clinical outcomes in t(11;14) multiple myeloma.

Moustafa, Muhamad Alhaj , Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Hwa, Yi L. , Lust, John A., Kyle, Robert A. , Kumar, Shaji , Moustafa, Muhamad Alhaj , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Dingli, David , Go, Ronald S.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8592-8592

10.1200/jco.2015.33.15_suppl.8592

Patterns of AKT, mTOR, ERK, and STAT3 pathway activation in MGUS, smoldering multiple myeloma, and multiple myeloma.

Larsen, Jeremy T. , Wellik, Linda, Kimlinger, Teresa K. , Kumar, Shaji , Ramakrishnan, Vijay , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8589-8589

10.1200/jco.2015.33.15_suppl.8589

Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma following early high dose therapy and autologous hematopoietic cell transplantation (SCT).

Kaufman, Gregory P., Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Kumar, Shaji , Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8583-8583

10.1200/jco.2015.33.15_suppl.8583

The prognostic significance of CD45 expression by clonal bone marrow plasma cells in multiple myeloma.

Morice, William G. , Timm, Michael, Lacy, Martha Q. , Hayman, Suzanne R. , Zeldenrust, Steven R., Kapoor, Prashant , Kumar, Shaji , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Morice, William George , Dispenzieri, Angela , Buadi, Francis K. , Lin, Yi , Dingli, David , Leung, Nelson , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8577-8577

10.1200/jco.2015.33.15_suppl.8577

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391)

Stewart, A. Keith, Mihaylov, Georgi , Rajnics, Péter , Suvorov, Aleksandr , Niesvizky, Rubén, Zojwalla, Naseem J., Palumbo, Antonio , Dimopoulos, Meletios Α. , Stewart, A. Keith, Rajkumar, S. Vincent , Masszi, Tamás , Oriol, Albert , Hájek, Roman , Rosiñol, Laura , Siegel, David S. , Goranova-Marinova, Vesselina S , Jakubowiak, Andrzej , Miguel, Jesús F. San , Ludwig, Heinz , Moreau, Philippe

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8525-8525

10.1200/jco.2015.33.15_suppl.8525

Survival trends in young patients with Waldenstrom macroglobulinemia (WM).

Vallumsetla, Nishanth, Ansell, Stephen M. , Kyle, Robert A. , Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Kapoor, Prashant , Paludo, Jonas , Gertz, Morie A. , Go, Ronald S. , Rajkumar, S. Vincent , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Leung, Nelson

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8596-8596

10.1200/jco.2015.33.15_suppl.8596

Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL).

Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Lust, John A., Suman, V., Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Leung, Nelson , Rajkumar, S. Vincent , Hogan, William J.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8595-8595

10.1200/jco.2015.33.15_suppl.8595

FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT)

Hulin, Cyrille , Belch, Andrew R. , Reece, Donna , Catalano, John, Qiu, Lugui , Schots, Rik , Marek, Jennifer, Chen, Guang , Ervin‐Haynes, Annette, Facon, Thierry T.F. , Dimopoulos, Meletios Α. , Pinto, Antonio , Ludwig, Heinz , Bahlis, Nizar Jacques , Cavo, Michèle , Moreau, Philippe , Qiu, Lugui , LeBlanc, Richard , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8524-8524

10.1200/jco.2015.33.15_suppl.8524

Citations

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment.

Kourelis, Taxiarchis , Kyle, Robert A. , Kumar, Shaji , Lacy, Martha Q. , Kapoor, Prashant , Lust, John A., Hayman, Suzanne R. , Zeldenrust, Steven R., Gertz, Morie A. , Buadi, Francis K. , Go, Ronald S. , Rajkumar, S. Vincent , Dingli, David , Lin, Yi , Leung, Nelson , Dispenzieri, Angela

Clinical outcomes in t(11;14) multiple myeloma.

Moustafa, Muhamad Alhaj , Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Hwa, Yi L. , Lust, John A., Kyle, Robert A. , Kumar, Shaji , Moustafa, Muhamad Alhaj , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Dingli, David , Go, Ronald S.

Patterns of AKT, mTOR, ERK, and STAT3 pathway activation in MGUS, smoldering multiple myeloma, and multiple myeloma.

Larsen, Jeremy T. , Wellik, Linda, Kimlinger, Teresa K. , Kumar, Shaji , Ramakrishnan, Vijay , Rajkumar, S. Vincent

Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma following early high dose therapy and autologous hematopoietic cell transplantation (SCT).

Kaufman, Gregory P., Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Kumar, Shaji , Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Rajkumar, S. Vincent

The prognostic significance of CD45 expression by clonal bone marrow plasma cells in multiple myeloma.

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391)

Survival trends in young patients with Waldenstrom macroglobulinemia (WM).

Vallumsetla, Nishanth, Ansell, Stephen M. , Kyle, Robert A. , Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Kapoor, Prashant , Paludo, Jonas , Gertz, Morie A. , Go, Ronald S. , Rajkumar, S. Vincent , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Leung, Nelson

Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL).

Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Lust, John A., Suman, V., Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Leung, Nelson , Rajkumar, S. Vincent , Hogan, William J.

FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT)